Jasper Therapeutics, Inc. (NASDAQ:JSPR) Forecasted to Post Q1 2024 Earnings of ($1.43) Per Share

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, May 6th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($1.43) for the quarter. HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($5.00) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 4th. The company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.65) by $0.15.

Several other equities research analysts have also recently issued reports on JSPR. Evercore ISI began coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. TD Cowen began coverage on Jasper Therapeutics in a research report on Monday, March 18th. They set an “outperform” rating for the company. Finally, Royal Bank of Canada started coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and an average price target of $64.29.

Jasper Therapeutics Stock Down 6.9 %

Shares of JSPR stock opened at $21.19 on Thursday. The company’s fifty day simple moving average is $25.52 and its two-hundred day simple moving average is $15.08. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The stock has a market cap of $319.12 million, a P/E ratio of -3.42 and a beta of 2.25.

Institutional Trading of Jasper Therapeutics

Institutional investors have recently bought and sold shares of the stock. Concurrent Investment Advisors LLC purchased a new stake in shares of Jasper Therapeutics in the first quarter valued at $599,000. Fernwood Investment Management LLC grew its holdings in Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after purchasing an additional 40,000 shares during the last quarter. Forefront Analytics LLC raised its position in Jasper Therapeutics by 59.7% in the 3rd quarter. Forefront Analytics LLC now owns 110,792 shares of the company’s stock worth $78,000 after purchasing an additional 41,425 shares during the period. Ieq Capital LLC purchased a new stake in Jasper Therapeutics in the 4th quarter worth about $43,000. Finally, Summit Trail Advisors LLC bought a new stake in Jasper Therapeutics in the third quarter worth about $46,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.